The Zhitong Finance App learned that Bank of America Securities released a research report saying that due to reduced platform subsidies and weak non-pharmaceutical business performance, the revenue forecast for Ali Health (00241.HK) for the 2027 fiscal year was lowered by 4% to 37.4 billion yuan, an increase of 9% year on year; the adjusted net profit forecast was lowered by 5% to 2.1 billion yuan, a decrease of 10% year on year. The target price for Ali Health was lowered by 17.6% from HK$5.1 to HK$4.2, reaffirming the “buy” rating.

The Zhitong Finance App learned that Bank of America Securities released a research report saying that due to reduced platform subsidies and weak non-pharmaceutical business performance, the revenue forecast for Ali Health (00241.HK) for the 2027 fiscal year was lowered by 4% to 37.4 billion yuan, an increase of 9% year on year; the adjusted net profit forecast was lowered by 5% to 2.1 billion yuan, a decrease of 10% year on year. The target price for Ali Health was lowered by 17.6% from HK$5.1 to HK$4.2, reaffirming the “buy” rating.